dude...go crawl under a rock.
enough of your bs.
Does anyone know what the next catalysts for this stock are? In terms of timing, is there anything beside the Phase IIa unblinding in Q3? Any idea of when the analyst meeting will take place in Q3?
#$%$ already...enough of your #$%$. You don't like it, SELL it....if you're short, well keep it.
Bigs - why don't you just get out of your position if you are long? Your efforts to manipulate this stock are unprecedented in my experience on these boards. The sad part is that you do a fantastic job of that because the avg daily volume on this stock is less than 100k.
You do realize that efficacy is THE WHOLE POINT of this trial.....you definitely put a lot of effort into trying to manipulate the price on a stock with thin float.
Canaccord Genuity analyst Jason Mills was out pounding the table on Sunshine Heart Inc (NASDAQ:SSH) Thursday, reiterating a Buy rating and a $7.50 price target, which represents a potential upside of 82.5% from where the stock is currently trading.
Mills noted, "We would be buyers of SSH common, which we think could move higher once the US trial “pause” is lifted and enrollment re-accelerates. We continue to believe SSH offers investors the opportunity to participate in a nascent growth company that is commercializing potentially disruptive technology for the treatment of moderate heart failure. We remain positive on the long-term prospects for SSH's differentiated technology in the treatment of Class III heart failure; thus, we maintain our BUY rating."